This article summarized the latest R&D progress of Dabigatran Etexilate Mesylate, the Mechanism of Action for Dabigatran Etexilate Mesylate, and the drug target R&D trends for Dabigatran Etexilate Mesylate.
Blue Earth Therapeutics released preclinical study results on the potency, lipophilicity, absorption, and efficacy of 225Ac-rhPSMA-10.1 in prostate cancer models, compared to 177Lu-rhPSMA-10.1. Both showed strong binding, excellent absorption, and similar lipophilicity.
This article summarized the latest R&D progress of Betahistine Hydrochloride, the Mechanism of Action for Betahistine Hydrochloride, and the drug target R&D trends for Betahistine Hydrochloride.
Results from the Phase 2 clinical trial examining VGT-309 indicate that the trial drug could enhance surgeons' capacity to locate hard-to-spot and previously missed tumors in real-time, thereby potentially benefitting patient outcomes.
This article summarized the latest R&D progress of Zoledronic Acid, the Mechanism of Action for Zoledronic Acid, and the drug target R&D trends for Zoledronic Acid.
Lassen Therapeutics is developing novel antibody treatments for fibro-inflammatory diseases and cancer, focusing on the IL-11R receptor (LASN01) and interleukin-18 binding proteins.
The CFTR protein is an ion channel mainly used to regulate the transepithelial movement of anions in mucus secretion tissues, thereby coordinating the balance of salt and fluid levels in mucus secretions.